Russell Investments Group Ltd. Sells 3,984 Shares of Illumina, Inc. (NASDAQ:ILMN)

Russell Investments Group Ltd. decreased its position in Illumina, Inc. (NASDAQ:ILMN - Free Report) by 9.2% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 39,463 shares of the life sciences company's stock after selling 3,984 shares during the quarter. Russell Investments Group Ltd.'s holdings in Illumina were worth $5,273,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in ILMN. Wellington Management Group LLP grew its position in shares of Illumina by 2.5% during the 3rd quarter. Wellington Management Group LLP now owns 30,946 shares of the life sciences company's stock worth $4,036,000 after buying an additional 755 shares during the period. XTX Topco Ltd bought a new stake in Illumina in the third quarter valued at about $226,000. Toronto Dominion Bank boosted its holdings in Illumina by 38.5% during the third quarter. Toronto Dominion Bank now owns 30,838 shares of the life sciences company's stock worth $4,022,000 after buying an additional 8,578 shares during the last quarter. TD Private Client Wealth LLC grew its position in shares of Illumina by 58.5% during the 3rd quarter. TD Private Client Wealth LLC now owns 382 shares of the life sciences company's stock worth $50,000 after buying an additional 141 shares during the period. Finally, M&T Bank Corp boosted its stake in Illumina by 3.4% during the 3rd quarter. M&T Bank Corp now owns 54,378 shares of the life sciences company's stock worth $7,091,000 after acquiring an additional 1,769 shares during the last quarter. 89.42% of the stock is owned by institutional investors.

Illumina Price Performance

NASDAQ:ILMN traded down $2.32 during trading hours on Friday, hitting $71.21. The stock had a trading volume of 2,639,652 shares, compared to its average volume of 2,269,690. The firm has a market capitalization of $11.28 billion, a price-to-earnings ratio of -9.27, a P/E/G ratio of 1.60 and a beta of 1.38. Illumina, Inc. has a one year low of $68.70 and a one year high of $156.66. The company has a 50 day simple moving average of $85.20 and a two-hundred day simple moving average of $120.80. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.77 and a quick ratio of 1.42.

Illumina (NASDAQ:ILMN - Get Free Report) last released its quarterly earnings results on Thursday, February 6th. The life sciences company reported $0.86 earnings per share for the quarter, missing the consensus estimate of $0.92 by ($0.06). Illumina had a negative net margin of 27.95% and a positive return on equity of 13.37%. Research analysts forecast that Illumina, Inc. will post 4.51 earnings per share for the current fiscal year.

Analyst Ratings Changes

ILMN has been the topic of a number of recent analyst reports. Morgan Stanley reduced their price target on shares of Illumina from $150.00 to $136.00 and set an "equal weight" rating on the stock in a research report on Tuesday, February 11th. Robert W. Baird decreased their price target on shares of Illumina from $127.00 to $90.00 and set a "neutral" rating for the company in a research note on Wednesday, March 5th. TD Cowen downgraded shares of Illumina from a "buy" rating to a "hold" rating and decreased their target price for the company from $177.00 to $140.00 in a research report on Friday, February 7th. Hsbc Global Res cut shares of Illumina from a "strong-buy" rating to a "hold" rating in a research report on Friday, February 28th. Finally, Royal Bank of Canada dropped their target price on Illumina from $128.00 to $112.00 and set an "outperform" rating on the stock in a report on Tuesday, April 8th. One analyst has rated the stock with a sell rating, ten have assigned a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $138.70.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.